vivo additive antiretroviral effect combined zidovudine foscarnet therapy human immunodeficiency virus infection ACTG Protocol Zidovudine antiretroviral activity human immunodeficiency virus HIV vitro inhibit HIV replication additive synergistic fashion vivo additive synergistic antiretroviral effect combined therapy symptomatic HIV-infected patients quantifiable serum HIV antigen weeks full-dose oral zidovudine therapy mg/day patients intravenous foscarnet mg/kg weeks continued oral zidovudine days zidovudine months Serum antigen concentrations patients period combined therapy mean serum antigen levels baseline value patients weeks vitro studies treatment zidovudine foscarnet additive vivo effect effect transient 